RECIST Versus Clinical Judgment in Assessing Progression in Advanced RCC

This segment addresses a frequent clinical dilemma: how closely to adhere to RECIST criteria in everyday practice. While clinical trials rely on rigid percentage thresholds to define response or progression, real world management requires contextual interpretation.

The panel discusses scenarios where tumor measurements increase marginally beyond RECIST thresholds but the patient remains clinically stable. Rather than automatically discontinuing therapy, clinicians often consider disease location, symptom burden, and pace of growth. Small increases in non threatening sites such as lymph nodes or small lung nodules may not justify immediate treatment change.

Radiographic nuance is emphasized. Necrotic changes, inflammatory responses after radiation, and imaging variability can complicate interpretation. Physicians highlight the importance of personally reviewing scans rather than relying solely on reports. Correlation with clinical status and laboratory trends provides critical context.

A case example illustrates how apparent progression in the liver was later determined to reflect imaging technique differences rather than true tumor growth. This underscores the value of due diligence before declaring treatment failure.

The discussion reinforces that while RECIST provides structure for trials, clinical oncology demands flexibility. Slow growth in asymptomatic patients may justify continued therapy, particularly if alternative options carry greater toxicity. The ultimate goal is to avoid prematurely discontinuing effective treatment based solely on numerical thresholds.